Penumbra Inc PEN stock is trading higher after the company reported better-than-expected first-quarter 2025 earnings and reaffirmed the 2025 forecast.The medical device company reported:Sales of $324.1 million, up 16.3% year over year (+16.9% in constant currency) and beating the consensus of $315.66 million.Adjusted EPS of 83 cents, beating the consensus of 67 cents.Revenue from global thrombectomy products grew to $226.5 million in the first quarter of 2025, an increase of 20.7%, or 21.2%, in constant cur ...

Penumbra, Inc. (PEN) reported first-quarter 2025 adjusted earnings per share (EPS) of 83 cents, which surpassed the Zacks Consensus Estimate by 25.8%. Adjusted EPS improved 102.4% year over year. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).GAAP earnings were $1 per share compared with 28 cents in the prior-year period.PEN Q1 RevenuesPenumbra registered revenues of $324.1 million in the reported quarter, up 16.3% year over year on a reported basis and 16.9% constant exchange rate ...

Penumbra, Inc. (NYSE:PEN) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO Jason Mills - EVP, Strategy Conference Call Participants Robbie Marcus - JPMorgan Lei Huang - Wells Fargo Pito Chickering - Deutsche Bank Macauley Kilbane - William Blair Bill Plovanic - Canaccord Travis Steed - Bank of America Ryan Zimmerman - BTIG Kallum Titchmarsh - Morgan Stanley Richard Newitter - Truist Ma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____ to _____ Commission File Number: 001-37557 Penumbra, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2025 Financial Results ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue increased to $324.1 million for the first quarter of 2025 compared to $278.7 million for the first quarter of 2024, an increase of 16.3%, or 16.9% in constant currency . The United States repre ...

ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024. U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024. Income from operations of $40.4 mil ...

PHILADELPHIA, April 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company’s current shareholders. Click here for additional information: https://kaskelalaw.com/case/penumbra/ The investigation seeks to determine whether Penumbra and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to investors in connection with recent corporate actions. Penumbra shareholders are encouraged to c ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Penumbra (PEN) , which belongs to the Zacks Medical - Instruments industry.When looking at the last two reports, this medical device maker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 14.89%, on average, in the last two quarters.For the most recent quarter, Penumbra was expected to post earnings of $0.91 p ...

Penumbra, Inc.’s (PEN) thrombectomy business is thriving, driven by growing sales of the U.S. vascular thrombectomy and CAVT (computer-assisted vacuum thrombectomy) line of products. The company’s robust product portfolio expansion is poised to drive growth in the upcoming quarters. Meanwhile, unfavorable foreign exchange and intense competition may pose operational risks for PEN.               In the past year, shares of this Zacks Rank #2 (Buy) company have increased 19.8% against the industry’s 18.4% dec ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company's shareholders.  The investigation seeks to determine whether Penumbra's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of Penumbra and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfirm.com/penumbra-inc/You ma ...